Why Moderna Stock Slipped Today
Shares of Moderna (NASDAQ: MRNA) slipped 3.7% on Monday as of the market close. The decline appeared to be related to a report in The New York Times that said the U.S. Food and Drug Administration (FDA) requested that COVID-19 vaccine makers expand their clinical trials for children between the ages of five to 11 before seeking emergency use authorization (EUA).
Although Moderna's shares fell on Monday, the delay in EUA filing for school-age children isn't all that bad for the company. The U.S. has already purchased more than enough COVID-19 vaccine doses to fully vaccinate all Americans this year, including younger children for whom the vaccines aren't yet authorized.
Image source: Getty Images.
Source Fool.com
